WaveBreak
Small-molecule therapeutics for neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
£12.4m Valuation: £90.0m 16.7x EV/Revenue -12.0x EV/EBITDA | Early VC | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 83 % | 820 % | (75 %) | 353 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (1164 %) | (1084 %) | (139 %) | (1256 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (1216 %) | (834 %) | (117 %) | (1255 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
WaveBreak, formerly known as Wren Therapeutics, is a biopharmaceutical company that develops small-molecule therapeutics to combat major neurodegenerative diseases like Parkinson's, Alzheimer's, and ALS. The company was spun out of the University of Cambridge and Lund University in 2016. Its scientific founders include Professor Sir Christopher Dobson, Professor Tuomas Knowles, and Dr. Samuel Cohen, who was also the founding CEO. In March 2022, Bart Henderson was appointed CEO, bringing extensive biotechnology industry experience.
The company's core technology focuses on a drug discovery platform designed to target and inhibit the transient, toxic protein intermediates, known as oligomers, which are understood to be a primary cause of neurotoxicity in protein misfolding diseases. This approach differs from conventional methods by focusing on the chemical kinetics of the protein misfolding process, aiming to block the generation of these harmful oligomers at their source. This strategy addresses the challenge that these oligomers are highly transient and difficult to target with traditional drug discovery techniques.
WaveBreak is advancing lead programs targeting α-synuclein for Parkinson's disease and amyloid-β for Alzheimer's disease. The company operates from headquarters in Boston, MA, and maintains a presence in Cambridge, UK. It has raised significant funding through multiple rounds, including a Series A round, to advance its pipeline and platform. The business model is centered on the discovery, development, and eventual commercialization of its novel therapeutics to address substantial unmet medical needs in the neurodegenerative space.
Keywords: neurodegenerative diseases, small-molecule therapeutics, protein misfolding, drug discovery, Alzheimer's disease, Parkinson's disease, ALS, oligomers, chemical kinetics, biopharmaceutical, α-synuclein, amyloid-β, drug development, transient protein intermediates, neurotoxicity, Cambridge spin-out, Boston biotechnology, clinical translation, therapeutic pipeline, Lewy body dementia.